Reneo Pharmaceuticals Stock Probability Of Bankruptcy
| RPHM Stock | USD 1.68 0.01 0.59% |
Reneo |
Reneo Pharmaceuticals Company odds of distress Analysis
Reneo Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Reneo Pharmaceuticals Probability Of Bankruptcy | Less than 23% |
Most of Reneo Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reneo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Reneo Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Reneo Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Reneo Pharmaceuticals financial health.
Is Reneo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reneo Pharmaceuticals. If investors know Reneo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reneo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Reneo Pharmaceuticals is measured differently than its book value, which is the value of Reneo that is recorded on the company's balance sheet. Investors also form their own opinion of Reneo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reneo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reneo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reneo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reneo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reneo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reneo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Reneo Pharmaceuticals has a Probability Of Bankruptcy of 23.0%. This is 46.87% lower than that of the Biotechnology sector and 58.06% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 42.25% higher than that of the company.
Reneo Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reneo Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics of similar companies.Reneo Pharmaceuticals is currently under evaluation in probability of bankruptcy category among related companies.
Reneo Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | (46.01 M) | ||||
| Shares Outstanding | 33.42 M | ||||
| Shares Owned By Insiders | 3.00 % | ||||
| Shares Owned By Institutions | 84.57 % | ||||
| Number Of Shares Shorted | 2.92 M | ||||
| Price To Book | 0.65 X | ||||
| EBITDA | (82.23 M) | ||||
| Net Income | (77.39 M) | ||||
| Cash And Equivalents | 126.85 M | ||||
| Cash Per Share | 5.18 X | ||||
| Total Debt | 1.46 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.84 X | ||||
| Book Value Per Share | 2.65 X | ||||
| Cash Flow From Operations | (63.68 M) | ||||
| Short Ratio | 17.80 X | ||||
| Earnings Per Share | (2.52) X | ||||
| Target Price | 1.68 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 55.98 M | ||||
| Total Asset | 107.44 M | ||||
| Retained Earnings | (218.47 M) | ||||
| Working Capital | 88.44 M | ||||
| Net Asset | 107.44 M |
About Reneo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reneo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Reneo Pharmaceuticals is a strong investment it is important to analyze Reneo Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reneo Pharmaceuticals' future performance. For an informed investment choice regarding Reneo Stock, refer to the following important reports:Check out Reneo Pharmaceuticals Piotroski F Score and Reneo Pharmaceuticals Altman Z Score analysis. To learn how to invest in Reneo Stock, please use our How to Invest in Reneo Pharmaceuticals guide.Note that the Reneo Pharmaceuticals information on this page should be used as a complementary analysis to other Reneo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Reneo Stock analysis
When running Reneo Pharmaceuticals' price analysis, check to measure Reneo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reneo Pharmaceuticals is operating at the current time. Most of Reneo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reneo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reneo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reneo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Reneo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reneo Pharmaceuticals. If investors know Reneo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reneo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Reneo Pharmaceuticals is measured differently than its book value, which is the value of Reneo that is recorded on the company's balance sheet. Investors also form their own opinion of Reneo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reneo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reneo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reneo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reneo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reneo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reneo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.